Skip to main content
Terug
Watch Compare

BIO-RAD LABORATORIES, INC.

Datakwaliteit: 100%
BIO-B
NYSE Manufacturing Measuring & Analyzing Instruments
€ 277,00
€ 0,00 (0,00%)
Marktkapitalisatie: 7,48 B
Prijs
€ 277,00
Marktkapitalisatie
7,48 B
Dagbereik
€ 277,00 — € 277,00
52-Weeksbereik
€ 225,29 — € 321,12
Volume
3
Openen € 277,00
50D / 200D Gem.
€ 279,39
0,85% below
50D / 200D Gem.
€ 280,40
1,21% below

Quick Summary

Belangrijkste Punten

Revenue declined -3,04% annually over 5 years
ROE of 10,96% — decent returns on equity
Net margin of 29,42% shows strong profitability
Debt/Equity of 0,18 — conservative balance sheet
Generating 374,60 M in free cash flow
P/E of 9,84 — trading at a low valuation

Groei

Revenue Growth (5Y)
-3,04%
Onder sectorgemiddelde (1,82%)
Revenue (1Y)0,65%
Earnings (1Y)N/A
FCF Growth (3Y)31,01%

Kwaliteit

Return on Equity
10,96%
Boven sectorgemiddelde (-53,41%)
ROIC0,38%
Net Margin29,42%
Op. Margin1,83%

Veiligheid

Debt / Equity
0,18
Onder sectorgemiddelde (0,31)
Current Ratio5,44
Interest Coverage0,96

Waardering

PE (TTM)
9,84
Boven sectorgemiddelde (-1,48)
P/B Ratio1,11
EV/EBITDA38,96
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E 9,8 -1,5
P/B 1,1 1,6
ROE % 11,0 -53,4
Net Margin % 29,4 -41,5
Rev Growth 5Y % -3,0 1,8
D/E 0,2 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) 0,65% Revenue Growth (3Y) -1,66%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -3,04% Earnings Growth (5Y) -34,96%
Profitability
Revenue (TTM) 2,58 B Net Income (TTM) 759,90 M
ROE 10,96% ROA 7,63%
Gross Margin 51,87% Operating Margin 1,83%
Net Margin 29,42% Free Cash Flow (TTM) 374,60 M
ROIC 0,38% FCF Growth (3Y) 31,01%
Safety
Debt / Equity 0,18 Current Ratio 5,44
Interest Coverage 0,96 Asset Turnover 0,26
Working Capital 2,32 B Tangible Book Value 5,77 B
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 9,84 Forward P/E N/A
P/B Ratio 1,11 P/S Ratio 2,89
PEG Ratio N/A Forward PEG N/A
EV/EBITDA 38,96 Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield 5,01%
Market Cap 7,48 B Enterprise Value 8,28 B
Per Share
EPS (Diluted TTM) 27,85 Revenue / Share 95,71
FCF / Share 13,88 OCF / Share 19,72
EPS CAGR (1Y) N/A EPS CAGR (5Y) -33,28%
EPS CAGR (10Y) 45,55%
Efficiency
CapEx / Revenue 6,10% FCF Conversion 49,30%
SBC-Adj. FCF 316,90 M Growth Momentum 3,69

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2,58 B 2,57 B 2,67 B 2,80 B 2,92 B
Net Income 759,90 M -1,84 B -637,32 M -3,63 B 4,25 B
EPS (Diluted) 27,85 -25,57 -21,82 -121,79 140,56
Gross Profit 1,34 B 1,38 B 1,43 B 1,57 B 1,64 B
Operating Income 47,20 M 269,00 M 337,80 M 482,62 M 489,43 M
EBITDA — — — — —
R&D Expenses 275,60 M 295,90 M 247,43 M 256,89 M 271,66 M
SG&A Expenses 844,30 M 814,00 M 841,72 M 827,83 M 879,57 M
D&A 165,40 M 151,60 M 145,90 M 137,30 M 133,80 M
Interest Expense 49,00 M 48,90 M 49,44 M 38,11 M 1,55 M
Income Tax 235,60 M -498,30 M -212,78 M -1,08 B 1,19 B

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 10,58 B 9,36 B 12,30 B 13,50 B 17,78 B
Total Liabilities 3,12 B 2,79 B 3,56 B 3,89 B 4,11 B
Shareholders' Equity 7,45 B 6,57 B 8,74 B 9,62 B 13,67 B
Total Debt 1,20 B 1,21 B 1,21 B — —
Cash & Equivalents 529,80 M 488,10 M 403,82 M 434,22 M 470,78 M
Current Assets 2,91 B 3,03 B 3,05 B 3,16 B 1,99 B
Current Liabilities 517,00 M 467,80 M 522,80 M 568,71 M 680,94 M